Please login to the form below

Not currently logged in
Email:
Password:

Novartis' patupilone fails phase III trial

Novartis has announced that its investigative compound, patupilone, has failed a phase III trial of patients with advanced ovarian cancer

Novartis has announced that its investigative compound, patupilone (EPO906), has failed a phase III trial of patients with advanced ovarian cancer, refractory or resistant to platinum-based therapy.

The compound was tested in a phase III study carried out in around 168 sites across 22 countries. The randomised study, which involved 829 patients with epithelial ovarian, primary fallopian or primary peritoneal cancer, compared patupilone with Doxil/Caelyx (pegylated liposomal doxorubicin).

The primary endpoint of the trial was overall survival. Secondary endpoints included progression-free survival, safety and overall response rate. Patupilone did not show a significant overall survival advantage. Based on this, Novartis does not plan to proceed with regulatory filings based on these data.

27th May 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics